Atara biotherapeutics announces first quarter 2022 financial results and operational progress

South san francisco, calif.--(business wire)--atara biotherapeutics, inc. (nasdaq: atra), a leader in t-cell immunotherapy, leveraging its novel allogeneic ebv t-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the first quarter 2022, recent business highlights and key upcoming catalysts. “atara is off to a strong start in 2022, and we look forward to the upcoming interim analysis of our ata188 phase 2 study
ATRA Ratings Summary
ATRA Quant Ranking